Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: ZYPREXA RELPREVV
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Olanzapine pamoate (Zyprexa Relprevv) is a long-acting injectable formulation of olanzapine indicated for schizophrenia.
It is clinically “olanzapine-like” in efficacy and metabolic burden, but it has a unique safety workflow: PDSS risk requires a structured observation period after every injection per label.
Compared with many depots, olanzapine pamoate is often reserved for situations where olanzapine’s clinical effect is clearly favored and the team can support required observation, transportation, and reliable follow-up.
The observation requirement and metabolic burden frequently dominate selection decisions more than pharmacologic differences versus other LAIs.
Olanzapine pamoate use is comparatively limited because the post-injection observation requirement adds staffing and facility complexity, and because olanzapine’s high metabolic burden constrains long-term use in some patients. When selected, injection visits can be leveraged for structured metabolic monitoring and relapse-prevention check-ins.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Olanzapine is a serotonin 5-HT2A and dopamine D2 antagonist with strong histamine H1 and muscarinic activity.
Antipsychotic effect is generally attributed to sustained D2 receptor occupancy with serotonergic modulation; sedation and anticholinergic effects reflect H1 and muscarinic activity.